CCO Oncology Podcast

Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

Episode Summary

Listen to expert commentary on emerging strategies in clinical trial development for treating patients with myelofibrosis, with a focus on alternatives to JAK inhibitors.

Episode Notes

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

• Navitoclax (BCL-XL/BCL-2 inhibitor)
• Pelabresib (BET inhibitor)
• Imetelstat (telomerase inhibitor)
• Luspatercept (erythroid maturation agent)
• Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV